Revolution Medicines Reports Q3 2026 Results Following RASONQUE Approval
Revolution Medicines (RVMD) reported its third-quarter 2026 financial results, highlighted by the successful commercial launch of RASONQUE following its August approval. The company generated $197.6 million in net product revenue from approximately five weeks of activity, serving over 5,000 unique patients. Payer coverage for pancreatic cancer reached 90%, with a significant portion of uptake (60%) originating from community oncology practices. Despite the commercial progress, the company reported a net loss of $407.5 million, driven by increased research and development expenses totaling $417.1 million as it scales clinical trials for RASONQUE and zoldonrasib. The company maintains a strong liquidity position with $3.7 billion in cash and marketable securities, bolstered by a recent $250 million funding tranche from Royalty Pharma.
Tickers: $RVMD
Topics: cash position market uptake patient volume product launch revenue
Read the full article at Motley Fool
Part of the story Vera Therapeutics Reports Q3 2026 Results Following TRUTAKNA Commercial Launch (9 articles)